L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
Year: 2022
Type: article
Source: Blood
Institutions: Universitätsklinikum Würzburg, University of Perugia, Azienda Ospedaliera S.Maria, Ministry of Interior and Administration, Clinica Universidad de Navarra, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Ludwig-Maximilians-Universität München, University of Würzburg, MorphoSys (Germany), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310127427